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Introduction {#sec001}
============

Prescription stimulants such as methylphenidate (MPH) are controversially discussed as potential drugs for pharmacological cognitive enhancement (PCE) in healthy individuals \[[@pone.0129805.ref001]--[@pone.0129805.ref005]\]. The increase of MPH prescriptions in the past two decades was supposed to coincide with an increased nonmedical use of MPH for PCE and relatively high prevalence rates of PCE among college students seemed to confirm the prediction \[[@pone.0129805.ref006],[@pone.0129805.ref007]\]. However, many studies failed to clearly define "nonmedical use" and considered different substances for PCE impeding the interpretation of the results \[[@pone.0129805.ref008]\]. Nevertheless, PCE is much more prevalent in the United States compared to Europe \[[@pone.0129805.ref008]\], but in both regions, MPH is the most frequently misused prescription drug for PCE \[[@pone.0129805.ref001],[@pone.0129805.ref009]\].

MPH elevates the neurotransmission of dopamine and noradrenalin by reuptake inhibition at the respective monoamine transporters, and was proposed to influence executive functions and working memory in healthy individuals \[[@pone.0129805.ref010],[@pone.0129805.ref011]\]. However, potential benefits and risks of PCE are both modulated by individual differences in response to drugs further depending on drug dose and task requirements. Consequently, procognitive effects of MPH are baseline-dependent (e.g., amelioration at low and impairment at high baseline performance) and afflicted with several trade-offs (e.g., improvement in one cognitive domain with the cost of impairments in other cognitive domains) as well as psychiatric side-effects \[[@pone.0129805.ref010]--[@pone.0129805.ref014]\].

The use of MPH for the treatment of ADHD is well-established and the potential side-effects are justified by the proven effectiveness \[[@pone.0129805.ref015]\]. However, this does not reclaim the use by healthy individuals without cognitive deficits. So far, it is unclear whether regular MPH use for PCE in healthy individuals is related to negative long-term cognitive, psychopathological, and neurobiological consequences \[[@pone.0129805.ref010],[@pone.0129805.ref014]\]. Nonetheless, previous studies found a higher prevalence of PCE among students with lower grades \[[@pone.0129805.ref001],[@pone.0129805.ref016],[@pone.0129805.ref017]\]. In general, the misuse of prescription stimulants might be associated with neuropsychological deficits prior to or as a consequence of PCE. Reske and colleagues found that occasional prescription stimulant users showed enhanced verbal fluency but, at the same time, more deficits in verbal learning, memory, and cognitive flexibility compared to stimulant-naïve controls. Therefore, they suggested that pre-existing cognitive deficits and subtle executive dysfunctions might be predictors for stimulant use \[[@pone.0129805.ref018],[@pone.0129805.ref019]\]. On the other hand, PCE itself might cause drug induced cognitive impairments as shown in a recent longitudinal study with recreational cocaine users \[[@pone.0129805.ref020]\]. Accordingly, the use of MPH might affect neuroplasticity and may, therefore, alter cognitive function, behavior, and personality of users \[[@pone.0129805.ref021]\].

Like amphetamine, MPH is a phenylethylamine derivate but shares the mechanism of catecholamine reuptake inhibition with cocaine \[[@pone.0129805.ref010]\]. The Zurich Cocaine Cognition Study (ZuCo2St) revealed that not only dependent but also recreational cocaine users showed significant deficits in the cognitive domains of attention, working and long-term memory, and executive functions \[[@pone.0129805.ref022]\]. Cocaine users also revealed higher levels of self-reported impulsivity and novelty seeking and more ADHD symptoms compared to stimulant-naïve controls \[[@pone.0129805.ref022],[@pone.0129805.ref023]\]. Moreover, cocaine use was associated with reduced neural sensitivity to social reward potentially explaining the users' deficits in social interactions such as less emotional empathy and a smaller social network \[[@pone.0129805.ref024],[@pone.0129805.ref025]\]. Studies considering the nonmedical use of MPH in healthy individuals have only addressed acute MPH effects on social cognition and behavior \[[@pone.0129805.ref026],[@pone.0129805.ref027]\], while the effects of chronic MPH use on social behavior are unknown so far.

The bioethical debate on neuroenhancement is based on the assumption that the use of putatively neuroenhancing stimulants already appears to be highly popular and that PCE use will further spread in the near future. However, these assumptions have been recently disputed \[[@pone.0129805.ref014],[@pone.0129805.ref028]\]. One argument against a future epidemic of PCE is that not everyone is equally interested in cognitive enhancement \[[@pone.0129805.ref029]\] assuming that personality has an essential impact on the willingness to use PCE \[[@pone.0129805.ref014]\]. Surprisingly, the influence of personality on the preference of PCE has scarcely been investigated yet, but Quednow proposed that in particular narcissistic and ambitious people might be more interested in PCE \[[@pone.0129805.ref014]\]. Preliminary data recently suggested that PCE is positively associated with ADHD symptoms, sensation seeking, and impulsivity \[[@pone.0129805.ref017],[@pone.0129805.ref030]\]. As the research on the so-called "dark triad" of personality traits revealed that subclinical narcissism is closely related to Machiavellianism and subclinical psychopathy \[[@pone.0129805.ref031]\], manipulative, opportunistic, and antisocial behaviors might be potential personality features of PCE users as well.

The primary goal of the present study was, therefore, a broad characterization of recently abstinent PCE users regarding their cognitive, behavioral, and personality profile. Based on previous studies showing a higher prevalence of PCE in students with lower grades \[[@pone.0129805.ref001],[@pone.0129805.ref016],[@pone.0129805.ref017]\] and demonstrating cognitive impairment in cocaine and other stimulant drug users \[[@pone.0129805.ref018]--[@pone.0129805.ref020],[@pone.0129805.ref022]\], we hypothesized that MPH misuse for PCE is associated with lower cognitive performance. Moreover, in PCE users we expected an increase in psychopathological loads and a specific personality structure similar to recreational stimulant users \[[@pone.0129805.ref023],[@pone.0129805.ref025],[@pone.0129805.ref032]\]. Specifically, we expected that PCE users show more pronounced narcissistic, opportunistic, Machiavellian, and impulsive facets, and less prominent sociable and prosocial behaviors.

Methods {#sec002}
=======

Participants {#sec003}
------------

Participants were recruited through flyer advertisements at the University of Zurich and the Swiss Federal Institute of Technology in Zurich, internet advertisement, and via e-mail as study participants from an earlier study on PCE had consented to be contacted again \[[@pone.0129805.ref009]\]. All participants had to pass an initial telephone screening to assess basic eligibility before they were invited for the assessment at the Psychiatric Hospital of the University of Zurich. Recently abstinent PCE users had to meet the following inclusion criteria: regular MPH use explicitly for PCE during the past 6 months and lifetime use of MPH for PCE on at least 25 occasions. Further inclusion criteria for all participants were 20 to 50 years of age and sufficient knowledge of German language. Exclusion criteria for all participants implied the following conditions: 1) severe medical diseases such as cardiovascular diseases, cancer, HIV, hepatitis, and diabetes; 2) present or prior axis-I psychiatric disorder according to DSM-IV; 3) no family history of a severe DSM-IV psychiatric disorder such as schizophrenia, bipolar disorder, or obsessive-compulsive disorder; 4) lifetime history of a neurological disorder such as meningitis, epilepsy, Tourette syndrome, Parkinson's disease, dementia, and head injury including loss of consciousness for more than 30 sec; 5) lifetime history of heroin use; 6) daily use of cannabis; 7) regular use of prescription drugs with effects on the central nervous system; and 8) use of other illegal drugs not mentioned before on more than 50 occasions. Prior to the testing session, participants had to abstain from MPH and illegal drugs for at least 72 hours and from alcohol for 24 hours. Adherence with these instructions was assessed by urine testing as described before \[[@pone.0129805.ref022]\]. The study was approved by the Cantonal Ethics Committee of Zurich. All study participants provided informed consent after being fully informed about the study details.

Drug use {#sec004}
--------

Current and past use of illegal substances and prescription drugs was assessed by a standardized Interview for Psychotropic Drug Consumption considering the date of last use, average quantity (mg, g, tablets, etc.) used weekly, and total lifetime duration of use \[[@pone.0129805.ref033]\]. Moreover, urine and hair testing revealed objective quantitative results about recent and past drug use. Urine samples were analyzed by liquid chromatography-tandem mass spectrometry (LC-MS/MS) regarding MPH and ritalinic acid ([S1 Method](#pone.0129805.s003){ref-type="supplementary-material"}) and by a semi-quantitative enzyme multiplied immunoassay method using a Dimension RXL Max (Siemens, Erlangen, Germany) for all other drugs \[[@pone.0129805.ref022]\]. MPH and illegal drug use during the past 6 months was assessed by 6-cm hair samples analyzed by LC-MS/MS as described in detail in [S2 Method](#pone.0129805.s004){ref-type="supplementary-material"} \[[@pone.0129805.ref022]\].

Cognitive functions {#sec005}
-------------------

For matching reasons, premorbid verbal intelligence was assessed by the Multiple-Choice Vocabulary Test (MWT-B). The following classical neuropsychological tests were used to assess cognition of PCE users and stimulant-naïve controls: four tests of the Cambridge Neuropsychological Test Automated Battery (CANTAB) were used to test sustained attention (Rapid Visual Processing, RVP), visuo-spatial memory (Paired Associates Learning, PAL), Spatial Working Memory (SWM), and Intra-Extra-Dimensional Set-Shifting (IED); the Letter-Number-Sequencing Task (LNST) was used to test verbal working memory; and the Rey Auditory Verbal Learning Test (RAVLT) was applied to test declarative verbal memory functions. Similar to our previous studies with cocaine users, four main z-scored cognitive domains (attention, working memory, declarative memory, executive functions) were defined and equally integrated in a global cognitive index (GCI, for details regarding the construction of the cognitive domains see [S3 Method](#pone.0129805.s005){ref-type="supplementary-material"}) \[[@pone.0129805.ref020],[@pone.0129805.ref022]\]. Furthermore, the Iowa Gambling Task (IGT) was used to measure decision-making. Points gained in the IGT were converted into Swiss Francs and disbursed to the participants.

Social cognition, interaction, and function {#sec006}
-------------------------------------------

Social cognitive functions such as cognitive and emotional empathy as well as theory-of-mind (ToM) were assessed with the Multifaceted Empathy Test (MET) and with the Movie for the Assessment of Social Cognition (MASC), respectively. Moreover, the Distribution Game and the Dictator Game tested social decision-making in an interaction paradigm, while the Social Network Questionnaire (SNQ) provided the number of currently available social contacts. Points gained in both interactive games were converted into Swiss Francs and disbursed to the participants. All tests have been described in detail before \[[@pone.0129805.ref024],[@pone.0129805.ref025]\].

Personality and psychiatric symptoms {#sec007}
------------------------------------

Psychiatric symptoms and personality disorders were assessed using the ADHD Self-Rating scale (ADHS-SR), the Structured Clinical Interview for DSM-IV Axis I (SCID-I Interview) and Axis II (SCID-II Questionnaire), and the Beck Depression Inventory (BDI). The Barratt Impulsiveness Scale (BIS-11), the Temperament Character Inventory (TCI), and the Machiavellianism questionnaire (MACH-IV) were included to assess personality. Additionally, the Delay Discounting task (DD) was used to assess delay of gratification/reward impulsivity (references to the neuropsychological tasks and all questionnaires are provided in Table A in [S1 File](#pone.0129805.s002){ref-type="supplementary-material"}).

Statistical analysis {#sec008}
--------------------

PCE users were matched with stimulant-naïve controls on the following variables: age, sex, years of education, proportion of students, verbal intelligence, and proportion of smokers. Quantitative data were analyzed by independent t-tests in order to compare PCE users with controls. For qualitative data, Chi^2^-tests were applied. Person's product moment correlations were used to evaluate the association between MPH use, cognitive performance, and personality scores and to explore inter-correlations between variables with significant group differences. All statistical analyses were conducted using SPSS Statistics 22 (Dynelytics, Zurich, Switzerland). For group comparisons, *p* \< 0.050 was set as the significance level, while for correlation analyses the significance threshold was set at *p* \< 0.010 in order to avoid an accumulation of alpha-error.

Results {#sec009}
=======

Ninety-four PCE users contacted us and showed interest in study participation. After a careful telephone screening, we were able to test 32 regular PCE users but only 25 of them met all inclusion criteria and were included in the final analyses (the trial profile is shown in [Fig 1](#pone.0129805.g001){ref-type="fig"}). PCE users were matched with 39 stimulant-naïve controls that were tested in the same way. As intended by the matching procedure both groups did not differ regarding age, sex, student status, years of education, verbal IQ, and smoking status, but PCE users reported significantly more ADHD symptoms than controls ([Table 1](#pone.0129805.t001){ref-type="table"}). According to the cut-off of the ADHS-SR questionnaire, five PCE users potentially met the DSM-IV criteria for ADHD but have not been diagnosed with this disorder before and were thus included in the study.

![Trial profile.\
ADHD: Attention Deficit Hyperactivity Disorder, ADHD-SR: Attention Deficit Hyperactivity Disorder Self-Rating scale, BIS-11: Barratt Impulsiveness Scale-11, CANTAB: Cambridge Neuropsychological Test Automated Battery, DD: Delay Discounting task, IDPC: Standardized Interview for Psychotropic Drug Consumption (self-report), IED: Intra-Extra Dimensional Set-Shifting, IGT: Iowa Gambling Task, LNST: Letter Number Sequencing Task, MASC: Movie for the Assessment of Social Cognition, MET: Multifaceted Empathy Test, MDMA: 3,4-Methylendioxy-N-methylamphetamin, MPH: methylphenidate, PAL: Paired Associates Learning, PCE: pharmacological cognitive enhancement, RAVLT: Rey Auditory Verbal Learning Test, RVP: Rapid Visual Information Processing, SCID I/II: Structural Clinical Interview for DSM-IV Axis I/II Disorders, SWM: Spatial Working Memory, TCI: Temperament and Character Inventory.](pone.0129805.g001){#pone.0129805.g001}

10.1371/journal.pone.0129805.t001

###### Demographic characteristics and drug use of stimulant-naïve healthy controls and individuals using methylphenidate for the purpose of pharmacological cognitive enhancement (PCE).

![](pone.0129805.t001){#pone.0129805.t001g}

                                                                     Controls (*n* = 39)        PCE users (*n* = 25)                            *X* ^*2*^ / *t*-test   *df*   *p* value
  ------------------------------------------------------------------ -------------------------- ----------------------------------------------- ---------------------- ------ ---------------
  *Demographics*                                                                                                                                                              
  Age                                                                26.2 (5.4)                 24.0 (3.0)                                      1.185                  62     0.072
  Women                                                              18 (46%)                   11 (44%)                                        0.029                  1      0.866
  Smoking status (yes)                                               24 (46%)                   15 (44%)                                        0.029                  1      0.866
  Student status (yes)                                               26 (67%)                   20 (80%)                                        1.340                  1      0.247
  Years of education                                                 11.6 (1.5)                 12.0 (1.0)                                      -1.161                 62     0.250
  Verbal IQ (MWT-B)                                                  106.0 (8.6)                104.8 (10.5)                                    0.507                  62     0.614
  ADHD-SR (range 0--54)                                              7.3 (5.1)                  12.9 (8.5)                                      -3.303                 62     **0**.**002**
  BDI sum score                                                      3.5 (4.2)                  4.8 (5.2)                                       -1.029                 62     0.308
  *Drug use*                                                                                                                                                                  
  Methylphenidate                                                                                                                                                             
  Tablets per week (10mg)                                            0                          2.5 (3.2)                                                                     
  Years of use                                                       0                          2.8 (1.5)                                                                     
  Cumulative dose (tablets)                                          0                          485.6 (1044.4)                                                                
  Last consumption (days)                                            NA                         40.5 (52.2), *n* = 24                                                         
      Hair analysis (pq/mg)                                          0                          84.2 (199.1)                                                                  
  Alcohol                                                                                                                                                                     
  Grams per week                                                     90.6 (77.0)                92.8 (76.0)                                     -0.114                 62     0.910
  Years of use                                                       8.6 (5)                    7.2 (3.5)                                       1.309                  62     0.195
  Tobacco                                                                                                                                                                     
  Cigarettes per day                                                 5.6 (8.0)                  4.8 (6.4)                                       0.456                  62     0.650
  Years of use                                                       5.9 (6.3)                  3.7 (3.6)                                       1.557                  62     0.125
  Cannabis                                                                                                                                                                    
  Grams per week                                                     0.2 (0.7)                  0.2 (0.4)                                       0.570                  62     0.571
  Years of use                                                       3.7 (4.4)                  3.3 (3.5)                                       0.385                  62     0.702
  Cumulative dose (grams)                                            965.4 (4423.9)             101.3 (164.0)                                   0.973                  62     0.334
  Last consumptions (days)                                           740.6 (1735.0), *n* = 24   23.5 (24.3), *n* = 13                           1.480                  35     0.148
      Positive urine testing[^a^](#t001fn002){ref-type="table-fn"}   4 (10%)                    2 (8%) [^a^](#t001fn002){ref-type="table-fn"}   0.064                  1      0.801
  Cocaine                                                                                                                                                                     
      Grams per week                                                 0                          0.1 (0.2)                                       -1.566                 62     0.122
      Years of use                                                   0 (0)                      1.1 (2.8)                                       -2.499                 62     0.**015**
      Cumulative dose (grams)                                        0.2 (0.9)                  15.8 (60.4)                                     -1.620                 62     0.110
      Last consumptions (days)                                       1104.8 (947.9), *n* = 3    319.2 (326.4), *n* = 9                          2.290                  10     **0**.**045**
      Positive urine testing[^a^](#t001fn002){ref-type="table-fn"}   0                          0                                                                             
      Positive hair testing[^a^](#t001fn002){ref-type="table-fn"}    0                          1 (4%)                                          1.585                  1      0.280
  Amphetamine                                                                                                                                                                 
      Grams per week                                                 0                          0.01 (0.02)                                     -1.718                 62     0.091
      Years of use                                                   0 (0)                      0.4 (1.3)                                       -2.064                 62     0.**043**
      Cumulative dose (grams)                                        0.003 (0.02)               0.6 (2.4)                                       -1.441                 62     0.155
      Last consumptions (days)                                       547.2 (258.0), *n* = 2     346.4 (724.9), *n* = 6                          0.367                  6      0.726
      Positive urine testing[^a^](#t001fn002){ref-type="table-fn"}   0                          1 (4%)                                          1.651                  1      0.199
      Positive hair testing[^a^](#t001fn002){ref-type="table-fn"}    0                          1 (4%)                                          1.585                  1      0.280
  MDMA                                                                                                                                                                        
      Tablets per week                                               0                          0.04 (0.2)                                      -1.399                 62     0.167
      Years of use                                                   0 (0)                      0.4 (1.0)                                       -2.342                 62     0.**022**
      Cumulative dose (tablets)                                      0.13 (0.4)                 3.4 (9.0)                                       -2.256                 62     **0**.**028**
      Last consumption (days)                                        3100.8 (1289.8), *n* = 2   31.3 (26.0), *n* = 3                            3.976                  6      **0**.**007**
      Positive hair testing[^a^](#t001fn002){ref-type="table-fn"}    0                          2 (8%)                                          3.221                  1      0.073

Data are means and standard deviations, or number and percent. Significant p-values are shown in bold.

^a^For cut-offs see [S1](#pone.0129805.s003){ref-type="supplementary-material"} and [S2](#pone.0129805.s004){ref-type="supplementary-material"} Methods.

ADHD-SR: Attention Deficit Hyperactivity Disorder Self-Rating scale, BDI: Beck Depression Inventory, IQ: intelligence quotient, MWT-B: Mehrfachwahl-Wortschatz-Test (vocabulary test), PCE: pharmacological cognitive enhancement.

On average, PCE users reported the intake of MPH for PCE since 2.8 years, used 2.5 tablets with 10mg MPH per week, have taken 486 MPH tablets in their lifetime, and were abstinent from MPH since 41 days ([Table 1](#pone.0129805.t001){ref-type="table"}). Six PCE users featured positive urine testing for ritalinic acid (mean 248ng/ml, range 3--1312 ng/ml), while only one PCE user revealed small traces of MPH (14 ng/ml). Self-reported weekly MPH use was significantly correlated with hair concentrations of MPH over the past 6 months (*r* = 0.640, *p* \< 0.001, *n* = 25).

PCE users showed no significant differences in the four cognitive domains and the GCI compared to controls ([Fig 2](#pone.0129805.g002){ref-type="fig"}). However, the executive functions showed a moderate effect size (*d* = 0.44) with regard to a superior performance of the PCE users, which was mainly explained by a significantly better performance in the strategy subscore of the SWM ([S1 Table](#pone.0129805.s006){ref-type="supplementary-material"}). In the IGT, PCE users gained more points in a shorter time ([Fig 3](#pone.0129805.g003){ref-type="fig"}), showing better performance in the second and in the fourth quartile ([S1 Fig](#pone.0129805.s001){ref-type="supplementary-material"}).

![Mean z-scores and standard errors of means for the global cognitive index (GCI) and four cognitive domains.](pone.0129805.g002){#pone.0129805.g002}

![Means and standard error of means of points gained and of processing time (sec) in the Iowa Gambling Task (IGT).\
\*\* *p*\< 0.010, and \*\*\**p* \< 0.001.](pone.0129805.g003){#pone.0129805.g003}

PCE users displayed higher levels of novelty seeking (mainly explained by significantly higher disorderliness) and revealed lower scores in social reward dependence (primarily due to significantly lower sentimentality) compared to controls. No group differences were found for delay discounting, but PCE users showed elevated self-reported impulsivity in the BIS-11 (specifically in the attention subscores), higher negativistic and antisocial personality traits in the SCID-II questionnaire, as well as higher Machiavellianism in the MACH-IV ([Table 2](#pone.0129805.t002){ref-type="table"}). Compared to controls, PCE users reported significantly fewer social contacts and their decisions in the social interaction tasks were more self-serving as they gave less money to the opposite player B while preferring higher payoffs for themselves ([Table 2](#pone.0129805.t002){ref-type="table"}).

10.1371/journal.pone.0129805.t002

###### Personality traits and social cognition and interaction of stimulant-naïve healthy controls and individuals using methylphenidate for the purpose of pharmacological cognitive enhancement (PCE).

![](pone.0129805.t002){#pone.0129805.t002g}

                                           Controls (*n*· = ·39)   PCE users (*n*· = ·25)   *t*-test   *df*   *p* value       Cohen\'s *d*
  ---------------------------------------- ----------------------- ------------------------ ---------- ------ --------------- --------------
  *Personality*                                                                                                               
  BIS-11 sum score                         61.6 (8.4)              66.8 (11.0)              -2.145     62     **0.036**       0.53
      BIS-11 Motor impulsiveness           21.7 (3.1)              23.9 (6.0)               -1.941     62     0.057           0.49
      BIS-11 Nonplanning impulsiveness     25.4 (4.2)              26.2 (5.1)               -0.690     62     0.493           0.18
      BIS-11 Attentional impulsiveness     14.6 (3.2)              16.8 (4.4)               -2.293     62     **0.025**       0.57
          BIS-11 Attention                 9.5 (2.3)               11.1 (2.8)               -2.428     62     **0.018**       0.60
          BIS-11 Cognitive Inflexibility   5.1 (1.7)               14.2 (3.3)               -1.284     62     0.204           0.33
  TCI Novelty Seeking                      21.8 (5.2)              24.6 (5.9)               -2.003     62     **0**.**050**   0.50
      TCI Exploratory excitability         7.9 (2.0)               8.3 (2.5)                -0.804     62     0.425           0.21
      TCI Impulsiveness                    4.3 (2.1)               4.6 (2.2)                -0.563     62     0.576           0.14
      TCI Extravagance                     5.4 (1.8)               5.9 (1.9)                -0.946     62     0.348           0.24
      TCI Disorderliness                   4.2 (1.8)               5.8 (1.7)                -3.566     62     **0**.**001**   0.84
  TCI Harm avoidance                       14.3 (5.6)              13.2 (6.9)               0.747      62     0.458           0.19
  TCI Reward Dependence                    16.9 (4.0)              14.6 (4.2)               2.182      62     **0**.**033**   0.54
      TCI Sentimentality                   6.5 (1.8)               5.4 (1.8)                2.299      62     **0**.**025**   0.57
      TCI Attachment                       6.5 (1.9)               5.5 (2.4)                1.850      62     0.069           0.47
      TCI Dependence                       4.0 (1.6)               3.7 (1.6)                0.565      62     0.574           0.15
  TCI Persistence                          4.3 (2.1)               3.4 (2.1)                1.681      62     0.098           0.42
  TCI Self-Directedness                    33.9 (6.0)              31.2 (6.4)               1.704      62     0.093           0.43
  TCI Cooperativeness                      33.5 (5.7)              31.5 (5.0)               1.375      62     0.174           0.35
  TCI Self-Transcendence                   10.2 (5.2)              9.2 (6.6)                0.695      62     0.490           0.18
  SCID-II Avoidant                         1.2 (1.4)               0.7 (1.1)                1.526      62     0.132           0.39
  SCID-II Dependent                        1.2 (1.1)               1.2 (1.0)                -0.035     62     0.973           0.01
  SCID-II Obsessive-compulsive             3.5 (1.8)               3.6 (1.6)                -0.256     62     0.799           0.07
  SCID-II Negativistic                     1.2 (1.4)               2.0 (1.4)                -2.486     62     **0**.**016**   0.61
  SCID-II Depressive                       1.1 (1.6)               1.4 (1.7)                -0.559     62     0.578           0.14
  SCID-II Paranoid                         1.6 (1.8)               1.8 (1.9)                -0.359     62     0.721           0.09
  SCID-II Schizotypal                      1.3 (1.6)               1.1 (1.0)                0.628      62     0.532           0.16
  SCID-II Schizoid                         0.7 (1.1)               1.2 (1.3)                -1.699     62     0.094           0.43
  SCID-II Histrionic                       1.9 (1.5)               2.5 (1.9)                -1.343     62     0.184           0.34
  SCID-II Narcissistic                     2.4 (2.5)               3.2 (2.3)                -1.241     62     0.219           0.32
  SCID-II Borderline                       2.4 (2.1)               2.3 (2.0)                0.303      62     0.763           0.08
  SCID-II Antisocial                       1.9 (1.6)               3.0 (2.7)                -2.011     62     **0**.**049**   0.50
  *Social cognition and interaction*                                                                                          
  MACH-IV sum score                        89.7 (12.3)             97.0 (10.5)              -2.561     61     **0**.**013**   0.64
  DD *k* parameter all                     0.012 (0.018)           0.022 (0.032)            -1.615     62     0.111           0.41
  MET Direct Empathy                       5.1 (1.2)               4.7 (1.2)                1.426      62     0.159           0.36
  MET Indirect Empathy                     4.8 (1.2)               4.6 (1.3)                0.420      62     0.676           0.11
  MET Cognitive Empathy                    25.4 (3.8)              23.0 (4.9)               2.273      62     **0**.**026**   0.56
  MASC Total ToM errors                    10.2 (4.6)              8.2 (3.2)                1.905      62     0.061           0.48
  Social network size (SNQ)                21.5 (7.3)              17.8 (5.3)               2.213      62     **0.031**       0.55
  Distribution game, payoff player B       19.0 (8.0)              17.0 (9.6)               0.882      62     0.381           0.23
  Dictator game, payoff player B           16.6 (12.2)             10.3 (9.4)               2.196      62     **0.032**       0.55

Data are means and standard deviations. Significant p-values are shown in bold. BIS: Barratt Impulsiveness Scale, DD: Delay Discounting task, MACH-IV: Machiavellianism Scale, MASC: Movie for the Assessment of Social Cognition, MET: Multifaceted Empathy Test, PCE: pharmacological cognitive enhancement, SCID-II: Structural Clinical Interview for DSM-IV Axis-II Disorders, SNQ: Social network questionnaire, TCI: Temperament and Character Inventory, ToM: Theory-of-Mind.

When assessing mental perspective-taking (ToM), PCE users made somewhat fewer errors in the MASC but the difference was not significant. Although PCE users revealed a slightly enhanced mental perspective-taking in the MASC, they showed, however, significantly lower cognitive empathy in the MET, indicating worse emotion recognition from complex picture material ([Table 2](#pone.0129805.t002){ref-type="table"}).

Neither cognitive performance nor personality scales were correlated with any MPH consumption parameters, indicating that the shown abnormalities of PCE users are likely not drug-induced. Machiavellianism was positively correlated with the TCI novelty seeking subscore disorderliness and the SCID-II negativistic score but negatively correlated with TCI social reward dependence and its subscore sentimentality. Not surprisingly, the ADHS-SR score was highly correlated with several BIS-11 scores but also with the SCID-II negativistic score. TCI disorderliness and the SCID-II antisocial score were positively correlated as well ([S2 Table](#pone.0129805.s007){ref-type="supplementary-material"}). These correlations reflect overlapping concepts of impulsivity and sociability as measured by the different questionnaires.

Discussion {#sec010}
==========

The aim of the study was to investigate whether regular PCE users show impaired cognitive functions and a specific pattern of personality traits. The study revealed two main findings: 1) recently abstinent PCE users and stimulant-naïve controls performed equally in most of the cognitive tasks but PCE users performed better in strategic thinking and decision-making, and 2) PCE users showed higher impulsivity, higher novelty seeking, higher Machiavellianism, and more pronounced antisocial and negativistic personality traits, in combination with lower social reward dependence compared to controls. In line with this personality pattern, they behaved more opportunistically in social interaction tasks, showed less cognitive empathy, and reported having a smaller social network. Importantly, these results cannot be explained by withdrawal effects as the mean abstinence duration from MPH was 41 days and only one subject has shown very small traces of MPH in the urine testing.

The finding that regular PCE users showed elevated attentional impulsivity but no cognitive impairment might indicate their motivation to use MPH for PCE. As it was shown that only individuals with low baseline performance show cognitive improvements using stimulant drugs \[[@pone.0129805.ref034]\], it is unlikely that MPH actually improved general cognitive functioning of the present PCE users because they already performed very well and sometimes better than controls. However, MPH is effective to treat symptoms of ADHD such as attentional impulsivity \[[@pone.0129805.ref010]\]. In fact, PCE users in the present study showed more ADHD symptoms and a previous study found procognitive effects of MPH specifically in healthy individuals with high impulsivity \[[@pone.0129805.ref035]\]. Thus, MPH might improve impulse control of PCE users, helping them to begin and sustain studying, rather than enhancing cognition directly. Consequently, not everyone benefits from MPH use and opposite cognitive effects (improvement and impairment) of the same MPH dose might even occur in the same individual depending on task requirements \[[@pone.0129805.ref010],[@pone.0129805.ref013]\]. As a specific predisposition such as high impulsivity is needed to benefit from MPH use and not everyone is willing to use PCE anyway \[[@pone.0129805.ref029]\], a forthcoming epidemic of MPH use for PCE is considered unlikely.

Although the groups did not significantly differ on the SCID-II narcissistic scale as initially hypothesized, PCE users showed more negativistic and antisocial personality traits, and higher Machiavellianism compared to controls. Interestingly, the SCID-II narcissistic subscale was significantly correlated with Machiavellianism (*r·* = ·0.38, *p·*\<·0.010) and the SCID-II negativistic subscale (*r·* = ·0.51, *p·*\<·0.001), confirming that narcissism, negativism, and Machiavellianism show a considerable phenomenological overlap. Thus, PCE users showed a specific pattern of personality traits that has been conceptualized as the "dark triad" \[[@pone.0129805.ref031]\]. Moreover, with their increased novelty seeking, higher impulsivity, and antisocial tendencies, PCE users share a number of personality features with recreational stimulant users \[[@pone.0129805.ref023],[@pone.0129805.ref036]\]. Additionally, PCE users behaved less prosocial in a money distribution game similar to recreational and dependent cocaine users as shown recently \[[@pone.0129805.ref025]\]. As intensity of cocaine use was not correlated with social decision-making, Hulka et al. suggested that the opportunistic behavior of stimulant users might be a stable trait and possibly a predisposition for the initiation of stimulant use \[[@pone.0129805.ref025]\]. Furthermore, similar to cocaine users, PCE users also displayed a smaller social network than controls \[[@pone.0129805.ref024]\]. This might be explained by the fact that PCE users are less sociable (as their personality profile suggests) and, thus, less integrated in social networks. Additionally, the smaller social network might mirror an intensified cost-benefit thinking of PCE users, and a more strategic selection of friends as supported by the present findings in IGT decision-making and strategic thinking.

Our findings are subject to some limitations. First, the number of PCE users was relatively small. This is obviously a threat to the statistical power of the reported analysis but, at the same time, a further implicit result of the study. In fact, it was hard to find individuals with regular MPH use for PCE who reported no concurrent regular use of other illegal drugs and no ADHD diagnosis. Second, the fact that the data were restricted to PCE users, who used MPH without regular co-use of illegal drugs of abuse, is a further limitation as it was shown previously that PCE users show a higher prevalence of illegal drug use compared to non-users \[[@pone.0129805.ref009],[@pone.0129805.ref017]\]. Therefore, the question arises, whether we tested only a very unique group within the already very specific group of PCE users. Nevertheless, the exclusion of PCE users with regular illegal drug use was inevitable in order to explain differences between PCE users and controls exclusively by the MPH use. Moreover, previous research revealed that PCE occurs most likely during short periods of exam preparation and daily or high dose use of PCE is rare \[[@pone.0129805.ref009]\]. Thus, through our inclusion criteria, we likely skimmed only the most intense PCE users. Third, we used a cross-sectional design but a longitudinal design would have been most appropriate to investigate cause-effect relationships between PCE drug use and changes in cognition and personality.

Conclusion {#sec011}
----------

This is the first study that broadly characterized individuals regularly using MPH for PCE by applying a comprehensive neuropsychological test battery in combination with a thorough personality assessment and urine and hair testing. Our findings indicate that the regular nonmedical MPH use for PCE over more than two years was not associated with cognitive deficits. PCE users performed equally to controls, or even better in tasks requiring strategic thinking, which disproves the assumption that PCE is a compensation for cognitive deficits \[[@pone.0129805.ref001],[@pone.0129805.ref016],[@pone.0129805.ref017]\]. As the personality profile of PCE users shared some features with recreational illegal stimulant users, such as higher novelty seeking and impulsivity, we propose instead that PCE users may aim to improve their impulse control in order to optimize their own learning compliance. PCE users were also found to be less prosocial, less emphatic, and more Machiavellianism, which is in line with their enhanced strategic thinking and planning behavior. Thus, PCE users may instrumentalize MPH as little helper \[[@pone.0129805.ref037]\] in order to maximize their own benefits. Finally, the overall personality profile of PCE users is highly specific disproving the often made assumption that PCE will widely spread in society.
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###### Means and standard errors for quartiles (Q1-Q4) and the net score (good minus bad cards) in the Iowa Gambling Task; \**p* \< 0.050, PCE: pharmacological cognitive enhancement.
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Click here for additional data file.

###### Neuropsychological Assessment.

References to neuropsychological tasks, interviews, and questionnaires used (Table A).
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Click here for additional data file.

###### Urine testing.
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Click here for additional data file.

###### Hair testing.
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###### Construction of the four cognitive domain scores.

Significant partial correlations with a *p*-level below 1% are shown and marked as: \*\**p* \< 0.010, \*\*\**p* \< 0.001. ADHD-SR: ADHD Self-Rating Scale, BIS: Barratt Impulsiveness Scale, MET: Multifaceted Empathy Test, NS: Novelty Seeking, PCE: pharmacological cognitive enhancement, RD: Reward Dependence, SCID I/II: Structural Clinical Interview for DSM-IV Axis I/II Disorders, SNQ: Social Network Questionnaire, SWM: Spatial Working Memory, TCI: Temperament and Character Inventory.
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Click here for additional data file.

###### Global cognitive index (GCI), the four cognitive domain z-scores, and neuropsychological test scores of stimulant-naïve healthy controls and individuals using methylphenidate for the purpose of pharmacological cognitive enhancement (PCE).

Data are means and standard deviations. Significant p-values are shown in bold. IED: Intra-Extra Dimensional Set-Shifting, LNST: Letter Number Sequencing Task, PAL: Paired Associates Learning, PCE: pharmacological cognitive enhancement, RAVLT: Rey Auditory Verbal Learning Test, RVP: Rapid Visual Information Processing, SWM: Spatial Working Memory.
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Click here for additional data file.

###### Pearson's product-moment correlations between test outcomes and clinical measures of social functioning with significant group differences between stimulant-naïve healthy controls (n = 39) and pharmacological cognitive enhancement users (*n* = 25).

Significant partial correlations with a *p*-level below 1% are shown and marked as: \*\**p* \< 0.010, \*\*\**p* \< 0.001. ADHD-SR: ADHD Self-Rating Scale, BIS: Barratt Impulsiveness Scale, MET: Multifaceted Empathy Test, NS: Novelty Seeking, PCE: pharmacological cognitive enhancement, RD: Reward Dependence, SCID I/II: Structural Clinical Interview for DSM-IV Axis I/II Disorders, SNQ: Social Network Questionnaire, SWM: Spatial Working Memory, TCI: Temperament and Character Inventory.
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Click here for additional data file.
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